MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
152.55
-1.84
-1.19%
Opening 10:40 03/28 EDT
OPEN
154.48
PREV CLOSE
154.39
HIGH
154.50
LOW
152.20
VOLUME
33.69K
TURNOVER
0
52 WEEK HIGH
218.88
52 WEEK LOW
143.52
MARKET CAP
19.21B
P/E (TTM)
-43.2815
1D
5D
1M
3M
1Y
5Y
Alnylam Pharmaceuticals Is Maintained at Outperform by BMO Capital
Dow Jones · 1d ago
Alnylam Pharmaceuticals Price Target Maintained With a $234.00/Share by BMO Capital
Dow Jones · 1d ago
BMO Capital Maintains Outperform on Alnylam Pharmaceuticals, Maintains $234 Price Target
Benzinga · 1d ago
Buy Rating Affirmed for Alnylam Pharmaceuticals on Strong Commercial Business and Expanding CNS Pipeline
TipRanks · 3d ago
Sum Up The Parts: QQQJ Could Be Worth $32
NASDAQ · 3d ago
Weekly Report: what happened at ALNY last week (0318-0322)?
Weekly Report · 3d ago
Noteworthy Friday Option Activity: CMG, BA, ALNY
NASDAQ · 5d ago
Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
NASDAQ · 6d ago
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.